News
‘New Drug Hidden Champion’ SCAI Therapeutics attracted investment of 31.4 billion won.
Author
SCAI Therapeutics
Date
2021-07-15 22:48
Views
598
According to the industry on the 14th of July, SCAI Therapeutics received an investment of 31.4 billion won in Series B. StoneBridge Ventures, IMM Investment, Kiwoom Capital, E-UM Private Equity, HB Investment, Foward Equity Partners, Timefolio Asset Management, Heungkuk Securities, and Lifecore Partners participated in the investment.
SCAI Therapeutics has attracted an 8 billion won investment on series A since it was founded in Daejeon in June 2019. It has also attracted Series B investment in about two years.
This company has original technology that enhances the bioavailability of drugs. Bioavailability refers to the effect of a certain amount of a drug in the body. Drugs show different efficacy depending on various factors such as crystal form, purity, and formulation form.
For example, SCAI Therapeutics has been developing a formulation of eye drops for the treatment of macular degeneration whereas it was conventionally administered as an injection into the eye. In a recent preclinical trial, eye drops proved the efficacy of suppressing the main cause of macular degeneration.
SCAI Therapeutics has increased the bioavailability of drugs to the level of several nanometers in drug particle size. With this investment as an opportunity, it plans to develop dry eye treatment, macular degeneration treatment, and diabetes treatment, and accelerate non-clinical and clinical trials. In addition, SCAI Therapeutics expects that its own technology can be applied not only to small molecules but also to proteins and antibodies.
Chul Hwan Kim, CEO of SCAI Therapeutics, said, “Our proprietary technology, MOASIS™, is a game-changing technology that can be applied to the development of new drugs that have not yet been commercialized. In the future, clinical trials will be conducted to confirm efficacy, and technology transfer or treatment development will be conducted.”
SCAI Therapeutics has attracted an 8 billion won investment on series A since it was founded in Daejeon in June 2019. It has also attracted Series B investment in about two years.
This company has original technology that enhances the bioavailability of drugs. Bioavailability refers to the effect of a certain amount of a drug in the body. Drugs show different efficacy depending on various factors such as crystal form, purity, and formulation form.
For example, SCAI Therapeutics has been developing a formulation of eye drops for the treatment of macular degeneration whereas it was conventionally administered as an injection into the eye. In a recent preclinical trial, eye drops proved the efficacy of suppressing the main cause of macular degeneration.
SCAI Therapeutics has increased the bioavailability of drugs to the level of several nanometers in drug particle size. With this investment as an opportunity, it plans to develop dry eye treatment, macular degeneration treatment, and diabetes treatment, and accelerate non-clinical and clinical trials. In addition, SCAI Therapeutics expects that its own technology can be applied not only to small molecules but also to proteins and antibodies.
Chul Hwan Kim, CEO of SCAI Therapeutics, said, “Our proprietary technology, MOASIS™, is a game-changing technology that can be applied to the development of new drugs that have not yet been commercialized. In the future, clinical trials will be conducted to confirm efficacy, and technology transfer or treatment development will be conducted.”